Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Excitement Around Next-Gen Gene-Editing

Executive Summary

Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.

You may also be interested in...



Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug

The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.

Biotech Drives Base Editing Into Clinic As Big Pharma Looks On

Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.

Prime Medicine Launches With $315m To Fund New Approach To Gene Editing

The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel